Технологии инактивации патогенов и качество концентратов тромбоцитов (обзор литературы)

Переливание концентратов тромбоцитов (КТ) является практически единственным быстрым и универсальным способом коррекции тромбоцитарной функции при широком спектре клинических ситуаций в детской гематологии. В силу короткого срока хранения КТ технологии инактивации патогенов крайне важны для снижения рисков иммунных реакций и инфекций. Однако существует большое количество исследований, свидетельствующих о том, что функция тромбоцитов при инактивации патогенов может меняться. В обзоре литературы рассмотрены лабораторные и клинические исследования, направленные на оценку значимости и направленности этих изменений, а также обсуждено практическое значение этих исследований для клинической работы с КТ.

технологии инактивации патогенов, тромбоциты, функциональная активность тромбоцитов, pathogen inactivation technologies, platelets, platelet functional activity

1. Атауллаханов ФИ, Воробьев АИ, Емельяненко ВМ, Пантелеев МА. Искусственные и лиофилизированные тромбоциты: реальная альтернатива тромбоконцентратам? Гематология и трансфузиология. 2010;55(5):14-9

2. Kaiser-Guignard J, Canellini G, Lion N, Abonnenc M, Osselaer JC, Tissot JD. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev. 2014;28(6):235-41.

3. Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother. 2011;38(1):8-18.

4. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion. 2004;44(10):1496-504.

5. Seghatchian J, Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apher Sci. 2012;46(2):221-9.

6. van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang. 2000;79(4):206-14.

7. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion. 2004;44(3):320-9.

8. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45(8):1335-41.

9. Johnson L, Loh YS, Kwok M, Marks DC. In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the INTERCEPT Blood system. Transfusion Med. 2013;23(2):121-9.

10. Carvalho H, Alguero C, Santos M, de Sousa G, Trindade H, Seghatchian J. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience. Transfus Apher Sci. 2006;34(2):187-92.

11. Apelseth T0, Bruserud 0, Wentzel-Larsen T, Bakken AM, Bj0rsvik S, Hervig T. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion. 2007;47(4):653-65.

12. Middelburg RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, van der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion. 2013;53(8):1780-7.

13. Galan AM, Lozano M, Molina P, Navalon F, Marschner S, Goodrich R, et al. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion. 2011;51(4):808-15.

14. Johnson L, Winter KM, Reid S, Hartkopf-Theis T, Marschner S, Goodrich RP, et al. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang. 2011; 101(3):208-14.

15. Reid S, Johnson L, Woodland N, Marks DC. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion. 2012;52(10):2094-103.

16. Castrillo A, Cardoso M, Rouse L. Treatment of buffy coat platelets in platelet additive solution with mirasol(®) pathogen reduction technology system. Transfus Med Hemother. 2013;40(1):44-8.

17. Ostrowski SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, et al. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion. 2010;50(10):2210-9.

18. Cookson P, Thomas S, Marschner S, Goodrich R, Cardigan R. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion. 2012;52(5):983-94.

19. Picker SM, Tauszig ME, Gathof BS. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion. 2012;52(3):510-6.

20. Abonnenc M, Sonego G, Crettaz D, Aliotta A, Prudent M, Tissot JD, et al. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB treated platelet concentrates. Transfusion. 2015;55(9):2219-30.

21. Zeddies S, De Cuyper IM, van der Meer PF, Daal BB, de Korte D, Gutiérrez L, et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion. 2014;54(9): 2292-300.

22. Osman A, Hitzler WE, Meyer CU, Landry P, Corduan A, Laffont B, et al. Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets. 2015;26(2):154-63.

23. Van Aelst B, Feys HB, Devloo R, Vanhoorelbeke K, Vandekerckhove P, Compernolle V. Riboflavin and amotosalen photochemicaltreatments of plateletconcentrates reduce thrombus formationkinetics in vitro. Vox Sang. 2015;108(4):328-39.

24. Ignatova AA, Karpova OV, Trakhtman PE, Rumiantsev SA, Panteleev MA. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution. Vox Sang. 2016;110(3):244-52.

25. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, et al. Effects of a new pathogen-reductiontechnology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005;45(6):911-9.

26. Prudent M, D'Alessandro A, Cazenave JP, Devine DV, Gachet C, Greinacher A,et al. Proteome changes in platelets after pathogen inactivation - an interlaboratory consensus. Transfus Med Rev. 2014;28(2):72-83.

27. Rinder HM, Smith BR. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion. 2003;43(1):2-6.

28. Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2013;(3):CD009072.

29. Kerkhoffs JL, van Putten WL, Novotny VM, TeBoekhorst PA, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209-17.

30. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35(1):5-17.

31. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005;45(8):1335-41.

32. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50(11):2362-75.

33. Stanojkovic Z, Balint B, Antic A, Todorovic M, Ostojic G, Pavlovic M. Clinical efficacy of riboflavin and ultraviolet light inactivated fresh frozen plasma evaluated with INR-quantification. Transfus Apher Sci. 2012;47(1):33-7.

34. Johansson PI, Simonsen AC, Brown PN, Ostrowski SR, Deberdt L, Van Hoydonck P, et al. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion. 2013;53(9):2043-52.

35. Ypma PF, van der Meer PF, Heddle NM, van Hilten JA, Stijnen T, Middelburg RA, et al. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open. 2016;6(1):e010156.